Top-line data from the Phase III DECLARE-TIMI 58 trial showed AstraZeneca PLC's diabetes therapy Farxiga (dapagliflozin) to be effective in reducing cardiovascular death and hospitalization for heart failure. However, the trial didn't meet its efficacy objective of cutting major adverse cardiovascular events in a statistically significant way, prompting some analysts to say the data would have minimal if any impact on boosting physician demand for the SGLT-2 inhibitor.
Farxiga is the last of the first wave of sodium glucose cotransporter 2 inhibitors to